[A new basic drug prospidin in the treatment of rheumatoid arthritis. III. Comparative analysis of prospidin and cyclophosphamide].

Abstract

A comparative study of the cytostatic drugs prospidin and cyclophosphamide used in equal doses for rheumatoid arthritis (RA) is reported. Clinical and immunologic effects were determined, and the nature and incidence of side effects and complications were compared. Prospidin showed a more pronounced antirheumatic effect, making for a smaller daily requirement of nonsteroid anti-inflammatory agents or hormones in hormone-dependent cases. Unlike cyclophosphamide, prospidin was not associated with severe side effects and complications precluding further use of the drug. Both drugs demonstrated a regulatory effect on RA-associated immunologic disorders.

• Authors: E V Benenson, B F Nemtsov, T M Ualieva
• Journal: Terapevticheskii arkhiv (Ter Arkh) Vol. 59 Issue 4 Pg. 76-9 ( 1987) ISSN: 0040-3660 [Print] Russia (Federation)
• Vernacular Title: Novoe bazisnoe sredstvo prospidin v terapii revmatoidnogo artrita. Soobshchenie III. Sravnitel'nyĭ analiz prospidina i tsiklofosfana.
• PMID: 3035735 (Publication Type: Comparative Study, English Abstract, Journal Article)

Chemical References

• Autoantibodies
• Piperazines
• Prospidium
• Cyclophosphamide
• Rheumatoid Factor

Topics

• Arthritis, Rheumatoid (drug therapy)
• Autoantibodies (analysis)
• Cell Migration Inhibition
• Cyclophosphamide (administration & dosage, adverse effects, therapeutic use)
• Humans
• Leukocytes (immunology)
• Peripheral Nervous System Diseases (chemically induced)
• Piperazines (therapeutic use)
• Prospidium (administration & dosage, adverse effects, therapeutic use)
• Rheumatoid Factor (analysis)
• Urination Disorders (chemically induced)